Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of preclinical research in an influenza animal model highlighting a new mechanism for enhancing the efficacy of monoclonal antibodies to treat viral infection and induce a protective response. Data demonstrate that selective engagement of an activating Fc receptor on dendritic cells by antiviral monoclonal antibodies induced protective CD8+ T cell adaptive responses. The paper, entitled “Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection,” was published in the October 8, 2020 online edition of Nature.

Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral Infection

Vir Biotechnology (VIR) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.

Vir Biotechnology (VIR) Looks Good: Stock Adds 6% in Session

GlaxoSmithKline

Vir Biotechnology Inc (NASDAQ: VIR) shares were rallying Tuesday after the company provided an update on its partnered COVID-19 treatment program. Vir's COVID-19 Antibody Update: Vir said it is advancing VIR-7831 — a fully human anti-SARS-CoV-2 monoclonal antibody it is developing along with GlaxoSmithKline plc (NYSE: GSK) — into a global Phase 3 trial dubbed COMET-ICE.

Vir Biotech, GlaxoSmithKline Advance COVID-19 Antibody Treatment Into Global, Late-Stage Trial

The global trial of the experimental antibody therapy will expand following promising safety results in early trial participants.

Antibody Therapy From GSK, Vir Goes To Phase 3 Trials

Vir Biotechnology and U.K.-based partner GlaxoSmithKline said they are expanding Phase 3, or final-phase, clinical trials for a possible Covid-19 antibody treatment. VIR stock jumped.

Vir Biotechnology, GlaxoSmithKline Expanding Phase 3 Trials For Covid-19 Treatment

Shares of Vir Biotechnology Inc. gained 5.3% in trading on Tuesday after the company said it is expanding the Phase 3 clinical trial for an experimental COVID-19 treatment.

Vir's stock rises as COVID-19 drug moves to late-study clinical trial

Vir Biotechnology Inc. (NASDAQ: VIR) shares jumped on Tuesday after the firm announced, in conjunction with GlaxoSmithKline PLC (NYSE: GSK), that they would be expanding their late-stage COVID-19 study.

Vir Biotechnology Expands Its Late-Stage COVID-19 Study

SAN FRANCISCO and LONDON, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study evaluating VIR-7831 for the early treatment of COVID-19 in patients who are at high risk of hospitalization. VIR-7831 (also known as GSK4182136) is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody that was selected based on its potential to neutralize the virus, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs (one of the major sites of infection). Following a positive assessment of unblinded safety data from the lead-in portion of the trial by an Independent Data Monitoring Committee on September 30, 2020, the COMET-ICE registrational study will now expand globally to additional sites in North America, South America and Europe.

Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19

The developers of a potential COVID-19 vaccine have moved trials to a third phase, hailing "rapid achievement" to date.

'Rapid achievement' allows vaccine trial to move to next phase

BioNTech SE

Both of these biotechs have promising COVID-19 programs. But one of them appears to have a clear edge.

Better Coronavirus Stock: BioNTech or Vir Biotechnology?

–  Largest -to-date  analysis of  serum  samples  from nearly  650 SARS-CoV-2-infected patients  –

Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell

Moderna

Novavax

Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.

4 Biotechs That Have More Than Doubled Thanks to Coronavirus

Investors bid its shares way up this year, but the market just slashed their value.

Should You Buy Vir Biotechnology Stock on the Dip?

SAN FRANCISCO, Sept.  09, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., chief medical officer of Vir will present at the Cantor Global Virtual Healthcare Conference on Tuesday, September 15th at 8:20 am PT/ 11:20 am ET.

Vir Biotechnology to Present at Cantor Global Virtual Healthcare Conference

SAN FRANCISCO, Sept.  08, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that Phil Pang, M.D., Ph.D., chief medical officer of Vir will virtually present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16 at 11:00 am PT / 2:00 pm ET.

Vir Biotechnology to Present at H.C. Wainwright 22nd Annual Global Investment Conference

SAN FRANCISCO, Sept.  01, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Janet Napolitano to its board of directors. Napolitano brings a breadth of leadership experience in both the public and private sectors to the organization. In addition to her former roles as the Governor of Arizona and the U.S. Secretary of Homeland Security under President Barack Obama, she served as the President of the University of California for the past seven years. Napolitano replaces Kristina Burow, who has resigned after four years as a founding director during which she was instrumental in setting Vir’s direction, building the team, and leading fundraising efforts for the company.

Vir Biotechnology Appoints Janet Napolitano to its Board of Directors

The treatment to prevent hospitalization from COVID-19 could be available in the first half of 2021.

Vir Biotechnology and GSK Launch Phase 2/3 Study of COVID-19 Antibody

Abbott Labs

Market Waits for Major Economic Data This Week.

Market Waits for Major Economic Data This Week

Shares of Vir Biotechnology Inc. VIR, +1.31% gained 9.2% in premarket trading on Monday when the company and GlaxoSmithKline GSK, -0.37% said they had begun dosing patients in the Phase 2/3 clinical study for their experimental COVID-19 antibody treatment.

Vir and GSK start Phase 2/3 trial for experimental COVID-19 treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage Covid-19 patients.

GlaxoSmithKline and partner Vir join the race to find a coronavirus antibody treatment

GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.

GSK, partner Vir join race to find COVID-19 antibody treatment

SAN FRANCISCO and LONDON, Aug.  31, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization.

Vir Biotechnology and GSK Start Phase 2/3 Study of COVID-19 Antibody Treatment

SAN FRANCISCO, Aug.  11, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Aurinia Pharmaceuticals

Let us take a look at two small biotech companies, VIR and AUPH, which are gearing up for their earnings release.

Drug/Biotech Stock Q2 Earnings Due on Aug 11: VIR and AUPH

SAN FRANCISCO, July  28, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the second quarter ended June 30, 2020 on Tuesday, August 11, 2020.

News for Vir Biotechnology Stock (VIR)